Expert Review of Neurotherapeutics最新文献_第7页

Current and emerging therapeutic advancements for Niemann-Pick disease type C: where are we now and what does the future hold? C型尼曼-匹克病目前和正在出现的治疗进展：我们现在在哪里，未来会怎样？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-06-01 Epub Date: 2026-04-20 DOI: 10.1080/14737175.2026.2661657

Andreas Hahn

{"title":"Current and emerging therapeutic advancements for Niemann-Pick disease type C: where are we now and what does the future hold?","authors":"Andreas Hahn","doi":"10.1080/14737175.2026.2661657","DOIUrl":"10.1080/14737175.2026.2661657","url":null,"abstract":"Introduction: Niemann-Pick Disease Type C (NPD Type C) is a rare lysosomal disease characterized by progressive neurovisceral manifestations due to abnormal lipid storage resulting from biallelic mutations in the NPC1 or NPC2 gene. Until recently, treatment was mainly symptomatic.Areas covered: This review summarizes the results of newer clinical trials evaluating efficacy and safety of new therapeutics, e.g. miglustat, cyclodextrins, arimoclomol, and N-Acetyl-L Leucine (NALL) for the treatment of NPD Type C. The PubMed database and the clinicaltrials.gov website were used for literature search and newest results posted.Expert opinion: Arimoclomol and NALL showed significant improvements of neurological symptoms and reasonable safety profiles in phase II/III trials. The recent approval of arimoclomol in combination with miglustat and NALL for patients with NPD type C has the potential to modify the standard of care and will hopefully improve the prognosis. However, the collection of real-world data is warranted to explore the real clinical value of these new medicaments. Cyclodextrins are also promising therapeutics that principally allow to correct basic pathophysiological mechanisms in NPD type C, but further research is needed.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"539-545"},"PeriodicalIF":3.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147728712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the differential diagnosis of generalized diabetic peripheral neuropathy. 探讨糖尿病周围神经病变的鉴别诊断。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-06-01 Epub Date: 2026-04-27 DOI: 10.1080/14737175.2026.2665649

Jenyfer Fuentes Mendoza, Marcio José Concepción Zavaleta, Alejandro Lopez Ramos, Camila Mondragón Portal, Luisa Graciela Dongo Dueñas, Jeny Justina Mendoza Godoy, Luis Concepción-Urteaga, José Paz-Ibarra

{"title":"Exploring the differential diagnosis of generalized diabetic peripheral neuropathy.","authors":"Jenyfer Fuentes Mendoza, Marcio José Concepción Zavaleta, Alejandro Lopez Ramos, Camila Mondragón Portal, Luisa Graciela Dongo Dueñas, Jeny Justina Mendoza Godoy, Luis Concepción-Urteaga, José Paz-Ibarra","doi":"10.1080/14737175.2026.2665649","DOIUrl":"10.1080/14737175.2026.2665649","url":null,"abstract":"Introduction: Diabetic peripheral neuropathy (DPN) is the most common chronic complication of diabetes mellitus and is frequently assumed to be the sole cause of neuropathic symptoms in patients with diabetes. This diagnostic simplification may lead to misdiagnosis, delayed treatment of alternative etiologies, and preventable neurological disability. Accurate differentiation between DPN and non-diabetic neuropathies remains a major clinical challenge.Areas covered: This narrative review examines the principal differential diagnoses of generalized DPN, integrating clinical presentation, disease tempo, electrophysiological patterns, and targeted laboratory evaluation. A structured literature search of PubMed, Scopus, and Web of Science (2015 2025) was conducted, focusing on inflammatory, nutritional, toxic, hereditary, amyloid, autoimmune, and systemic causes of peripheral neuropathy. Emerging diagnostic tools, including biomarkers and advanced neurophysiological techniques, are also discussed, and a practical diagnostic algorithm is proposed to support real-world clinical decision-making.Expert opinion: DPN should be regarded as a diagnosis of exclusion rather than a default explanation in patients with diabetes. A phenotype-driven and structured diagnostic approach is essential to reduce diagnostic anchoring, prevent iatrogenic harm, and enable early identification of treatable neuropathies, ultimately improving neurological outcomes and precision medicine strategies.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"569-583"},"PeriodicalIF":4.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Game changer: direct observation to improve personalized psychotherapy in adolescent gaming disorder. 游戏改变者：直接观察改善青少年游戏障碍的个性化心理治疗。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-06-01 Epub Date: 2026-04-29 DOI: 10.1080/14737175.2026.2661664

Lucien Rochat, Sofia Arango Arroyave, Sophia Achab

引用次数: 0

The value and risks of antidepressant therapy in Alzheimer's disease: a field update and its clinical implications. 抗抑郁药治疗阿尔茨海默病的价值和风险：领域更新及其临床意义

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-06-01 Epub Date: 2026-04-06 DOI: 10.1080/14737175.2026.2653170

Polona Rus Prelog, Blanka Kores Plesničar, Matija Zupan, Senta Frol, Milica Gregorič Kramberger

{"title":"The value and risks of antidepressant therapy in Alzheimer's disease: a field update and its clinical implications.","authors":"Polona Rus Prelog, Blanka Kores Plesničar, Matija Zupan, Senta Frol, Milica Gregorič Kramberger","doi":"10.1080/14737175.2026.2653170","DOIUrl":"10.1080/14737175.2026.2653170","url":null,"abstract":"Introduction: Depression is one of the most frequent and disabling neuropsychiatric syndromes in Alzheimer's disease (AD), yet antidepressant use is still largely extrapolated from late‑life depression and is poorly aligned with emerging evidence on 'neurodegenerative depression' and disease‑modifying therapies. This article critically re‑examines the clinical value and risks of antidepressants in AD.Areas covered: Drawing on a narrative search of PubMed/MEDLINE and Embase (January 2000-December 2025) and targeted review of recent guidelines and anti‑amyloid trials, the article synthesizes randomized and observational data on efficacy and safety across antidepressant classes, highlighting modest and inconsistent benefits alongside adverse outcomes such as falls, hyponatremia, bleeding, mortality and possible acceleration of cognitive decline. It integrates mechanistic work on synaptic loss, neuroinflammation and network disruption, discusses the exclusion of depressed patients from anti‑amyloid trials, and reviews rapid‑acting, neuromodulatory and psychosocial strategies within a proposed precision‑prescribing framework based on biomarkers, vascular burden and symptom dimensions.Expert opinion: Monoaminergic antidepressants in AD should not be abandoned but repositioned as time‑limited, closely monitored options for clearly defined, functionally impairing depressive syndromes, embedded in multimodal care rather than used as default, long‑term treatment for non‑specific distress. Future priorities include biomarker‑stratified AD depression trials, evaluation of interactions with anti‑amyloid therapies and rigorous testing of non‑monoaminergic interventions.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"523-537"},"PeriodicalIF":4.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147622099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rationale and study design for the first precision medicine randomized placebo-controlled trial in the 16p11.2 deletion syndrome. 16p11.2缺失综合征首个精准医学随机安慰剂对照试验的基本原理和研究设计。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-06-01 Epub Date: 2026-05-04 DOI: 10.1080/14737175.2026.2655767

Hannah M Rea, Julia T Mattson, Vardan Arutiunian, Alyssa Verdes, Suvekcha Bhattachan, Megha Santhosh, Abigail Garcia, Anika Ajwani, Meaghan Bowen, Susan Faja, Ellen Hanson, Katherine Pawlowski, Robin P Kochel, Lisa Prock, Jeremy Veenstra-VanderWeele, Karen Walton-Bowen, Adam Vogel, Angela Morgan, Sara Jane Webb, Paul P Wang

{"title":"Rationale and study design for the first precision medicine randomized placebo-controlled trial in the 16p11.2 deletion syndrome.","authors":"Hannah M Rea, Julia T Mattson, Vardan Arutiunian, Alyssa Verdes, Suvekcha Bhattachan, Megha Santhosh, Abigail Garcia, Anika Ajwani, Meaghan Bowen, Susan Faja, Ellen Hanson, Katherine Pawlowski, Robin P Kochel, Lisa Prock, Jeremy Veenstra-VanderWeele, Karen Walton-Bowen, Adam Vogel, Angela Morgan, Sara Jane Webb, Paul P Wang","doi":"10.1080/14737175.2026.2655767","DOIUrl":"10.1080/14737175.2026.2655767","url":null,"abstract":"Chromosome 16p11.2 deletion syndrome is a genetic syndrome that includes difficulties in speech, language, and motor coordination. Arbaclofen, a selective GABA-B receptor agonist, has improved motor functioning and memory in mouse models. Prior clinical trials of arbaclofen in fragile X syndrome and autism spectrum disorder suggested benefit for social communication. L16hthouse (NCT04271332) is a multi-site, double-blind, randomized, placebo-controlled phase 2 trial to evaluate safety, efficacy, and tolerability of arbaclofen compared in 60 youths with 16p11.2 deletion syndrome (5 to 17:11 years) randomized on a 1:1 ratio. Primary outcomes included speech articulation, measured by the Goldman Fristoe Test of Articulation 3 (GFTA-3). Secondary outcomes included objective dysarthria indices, memory, motor control, and cognitive function, assessed with both standardized clinical measures and novel, computer-based assessments with automated scoring. Exploratory outcomes included attention, autism traits, and electrophysiological responses. L16hthouse is the first randomized trial in 16p11.2 deletion syndrome and uses an array of novel outcome measures to assess potential benefit in this population. In addition to providing potential insights about the safety, efficacy, and tolerability of arbaclofen, L16hthouse will provide an initial assessment of how these developmental outcome measures perform in a clinical trial across a broad age range.Clinical trial registration number: NCT04271332; 2020-02-13.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"597-607"},"PeriodicalIF":4.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147812793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When and in what patient segments are low-intensity and remote interventions valuable for treating symptoms of post-concussion syndrome. 低强度和远程干预对治疗脑震荡后综合征的症状有价值的时间和对象。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-06-01 Epub Date: 2026-04-29 DOI: 10.1080/14737175.2026.2665651

María Julieta Russo, Fernando Salvat

引用次数: 0

Do people with bipolar disorder have a greater risk of dementia in later life? 双相情感障碍患者在以后的生活中患痴呆的风险更大吗？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-05-01 Epub Date: 2026-03-31 DOI: 10.1080/14737175.2026.2652297

Breno Satler Diniz

引用次数: 0

Novel treatment strategies for the management of refractory bipolar disorder. 管理难治性双相情感障碍的新治疗策略。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-05-01 Epub Date: 2026-03-31 DOI: 10.1080/14737175.2026.2653176

Ezequiel Lafont, Arielle M Morris, Krishna Patel, Sydney Demchak, Candace Chan, Timothy R Rice

{"title":"Novel treatment strategies for the management of refractory bipolar disorder.","authors":"Ezequiel Lafont, Arielle M Morris, Krishna Patel, Sydney Demchak, Candace Chan, Timothy R Rice","doi":"10.1080/14737175.2026.2653176","DOIUrl":"10.1080/14737175.2026.2653176","url":null,"abstract":"Introduction: Bipolar disorder is often treatable with conventional psychopharmacology. Despite the availability of numerous established treatments for bipolar disorder, cases of treatment resistance persist. The identification of optimal therapies proves challenging, as the term treatment resistance lacks a clear, standardized definition. Ambiguity in defining frequency, duration, and number of medication failures across the different subtypes of refractory bipolar disorder contributes to an inconsistent framework which negatively impacts both clinical decision making and clinical outcomes.Areas covered: This review article surveys updated novel treatments for the subtypes of refractory bipolar disorder in adult and pediatric populations. Treatment-resistant acute mania, rapid cycling, and bipolar depression in adult populations are reviewed, and studies in pediatric treatment-resistant bipolar disorder are overviewed. A literature search was conducted using MEDLINE and focused on studies published between 2015 and 2025 to highlight the latest research findings in this area of interest.Expert opinion: Future directions offer optimism through precision medicine, but a comprehensive conclusive survey of treatment-resistant bipolar disorder remains premature in its current state of research. Current challenges underscore the importance of creating a clearly defined classification system to improve diagnostic clarity and the consistency of research and clinical outcomes.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"461-476"},"PeriodicalIF":4.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Centanafadine for the treatment of attention-deficit/hyperactivity disorder in adults: a plain language summary of publication. 辛他那定治疗成人注意力缺陷/多动障碍：发表摘要

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-05-01 Epub Date: 2026-04-01 DOI: 10.1080/14737175.2026.2642839

Caroline L Ward, Jessica Madera-McDonough, Mary Hobart, Denise Chang, Na Jin, Taisa Skubiak, Michael Liebowitz

引用次数: 0

Pharmacogenomics of anti-seizure medications in epilepsy: a systematic review of genetic predictors of response and tolerance. 抗癫痫药物的药物基因组学：反应和耐受性遗传预测因子的系统综述。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2026-05-01 Epub Date: 2026-03-30 DOI: 10.1080/14737175.2026.2647028

Ainara Barguilla, Pau Riera, Victoria Ros-Castelló, Elena Muino, Alba Sierra-Marcos

{"title":"Pharmacogenomics of anti-seizure medications in epilepsy: a systematic review of genetic predictors of response and tolerance.","authors":"Ainara Barguilla, Pau Riera, Victoria Ros-Castelló, Elena Muino, Alba Sierra-Marcos","doi":"10.1080/14737175.2026.2647028","DOIUrl":"10.1080/14737175.2026.2647028","url":null,"abstract":"Background: Effectiveness and tolerability of anti-seizure medications (ASM) vary widely among individuals with epilepsy. Genetic polymorphisms may influence pharmacokinetic and pharmacodynamic responses, yet available evidence is heterogeneous and inconsistently translated into clinical practice.Methods: A systematic search of eight databases (2000-2024) identified observational studies assessing associations between genetic variants and ASM response or adverse drug reactions. The review protocol was registered in PROSPERO (CRD420251237140). Two reviewers independently performed screening, data extraction and quality assessment using the Newcastle-Ottawa Scale. Owing to methodological heterogeneity, a narrative synthesis was conducted.Results: A total of 168 studies were eligible. The strongest and most consistent associations involved HLA-B*15:02 and HLA-A*31:01 as predictors of severe cutaneous adverse reactions to carbamazepine, oxcarbazepine and phenytoin. CYP2C9 variants showed reproducible links to phenytoin toxicity. Associations involving ABCB1, SCN1A, SCN2A, GABRA1 and UGT2B7 for treatment response were reported, but findings varied across ASM classes and populations. Substantial ethnic variability was observed, particularly in Asian cohorts.Conclusions: Only a limited number of genetic polymorphisms currently demonstrate sufficient consistency for clinical translation, mainly HLA alleles predicting severe cutaneous reactions and CYP2C9 variants associated with phenytoin toxicity. Larger multiethnic studies with standardized outcome definitions are needed to clarify the therapeutic role of additional markers and support broader pharmacogenomic implementation.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"485-495"},"PeriodicalIF":4.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147510698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0